Dr. Mark Ward

• LA Norris, F Abu Saadeh, M Ward, SA O'Toole, Z Marchocki, N. Ibrahim, N Gleeson, Development and validation of a risk model for prediction of venous thromboembolism in gynaecological cancer patients, Thrombosis Research, International Congress on Thrombosis and Haemostasis Issues in Cancer, Bergamo, April 2018, 164, (Supplement 1), Elsevier, 2018, ppS183 - S184Oral Presentation, 2018, DOI
• Z. Marchocki, N. Gleeson, F. Abu Saadeh, M.P. Ward, S.A. O'Toole, L.A. Norris, Fibrinogen, D-Dimers and thrombin generation assays as predictors of the risk of recurrent VTE in patients with gynaecological malignancies, Thrombosis Research, International Congress on Thrombosis and Haemostasis Issues in Cancer, Bergamo, April 2018, 164, (Supplement 1), 2018, pp200 - 200Meeting Abstract, 2018, DOI
• Jabakhanji, S.B., Boland, F., Ward, M., Biesma, R., Body Mass Index Changes in Early Childhood, Journal of Pediatrics, 202, 2018, p106 - 114Journal Article, 2018
• Useckaite Z, Ward MP, Trappe A, Reilly R, Lennon J, Davage H, Matallanas D, Cassidy H, Dillon ET, Brennan K, Doyle SL, Carter S, Donnelly S, Linnane B, McKone EF, McNally P, Coppinger JA., Increased extracellular vesicles mediate inflammatory signalling in cystic fibrosis., Thorax, 75, (6), 2020, p449-458Journal Article, 2020, DOI , TARA - Full Text
• O'Toole SA, Spillane C, Huang Y, Fitzgerald MC, Ffrench B, Mohamed B, Ward M, Gallagher M, Kelly T, O'Brien C, Ruttle C, Bogdanska A, Martin C, Mullen D, Connolly E, McGarrigle SA, Kennedy J, O'Leary JJ., Circulating tumour cell enumeration does not correlate with Miller-Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy., Breast cancer research and treatment, 181, (3), 2020, p571-580Journal Article, 2020, DOI
• Norris LA, Ward MP, O'Toole SA, Marchocki Z, Ibrahim N, Khashan AS, Abu Saadeh F, Gleeson N., A risk score for prediction of venous thromboembolism in gynecologic cancer: The Thrombogyn score., Res Pract Thromb Haemost, 4, (5), 2020, p848-859Journal Article, 2020, DOI
• O'Toole SA, Huang Y, Norris L, Power Foley M, Shireen R, McDonald S, Kamran W, Ibrahim N, Ward M, Thompson C, Murphy C, D'Arcy T, Farah N, Heron E, O'Leary JJ, Abu Saadeh F, Gleeson N., HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status., Gynecologic oncology, 2021Journal Article, 2021, DOI
• Ward, Mark P., Saadeh, Feras Abu, O'Toole, Sharon A., O'Leary, John J., Gleeson, Noreen, Norris, Lucy A., Procoagulant activity in high grade serous ovarian cancer patients following neoadjuvant chemotherapy-The role of the activated protein C pathway, Thrombosis Research, 200, 2021, p91 - 98Journal Article, 2021, DOI
• Kane, L.E., Ward, M.P., Norris, L.A et al., Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell?, Molecular Cancer, 20, 2021, p59-Journal Article, 2021, DOI
• Ward MP, Spiers JP., Protein phosphatase 2A regulation of markers of extracellular matrix remodelling in hepatocellular carcinoma cells: functional consequences for tumour invasion., British journal of pharmacology, 174, (10), 2017, p1116-1130Journal Article, 2017, DOI
• Shields S, Conroy E, O'Grady T, McGoldrick A, Connor K, Ward MP, Useckaite Z, Dempsey E, Reilly R, Fan Y, Chubb A, Matallanas DG, Kay EW, O'Connor D, McCann A, Gallagher WM, Coppinger JA., BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer., Oncotarget, 9, (21), 2018, p15673-15690Journal Article, 2018, DOI
• Mark P. Ward, Extracellular vesicles in ovarian cancer-A role in venous thromboembolism?, Thrombosis Update, 3, 2021Journal Article, 2021, DOI
• Di Fiore R, Suleiman S, Pentimalli F, O'Toole SA, O'Leary JJ, Ward MP, Conlon NT, Sabol M, Ozreti" P, Erson-Bensan AE, Reed N, Giordano A, Herrington CS, Calleja-Agius J., Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview., International journal of molecular sciences, 22, (8), 2021Journal Article, 2021, DOI
• Riccardo Di Fiore, Sherif Suleiman, Ana Felix, Sharon A O'Toole, John J O'Leary, Mark P Ward, James Beirne, Maja Sabol, Petar Ozretić, Angel Yordanov, Mariela Vasileva-Slaveva, Stoyan Kostov, Margarita Nikolova, Ian Said-Huntingford, Duncan Ayers, Bridget Ellul, Francesca Pentimalli, Antonio Giordano, Jean Calleja-Agius, An Overview of the Role of Long Non-Coding RNAs in Human Choriocarcinoma, International Journal of Molecular Sciences, 22, 2021Journal Article, 2021, DOI
• Di Fiore R, Suleiman S, Drago-Ferrante R, Felix A, O'Toole SA, O'Leary JJ, Ward MP, Beirne J, Yordanov A, Vasileva-Slaveva M, Subbannayya Y, Pentimalli F, Giordano A, Calleja-Agius J., LncRNA MORT (ZNF667-AS1) in Cancer-Is There a Possible Role in Gynecological Malignancies?, International journal of molecular sciences, 22, (15), 2021Journal Article, 2021, DOI
• Spillane CD, Cooke NM, Ward MP, Kenny D, Blackshields G, Kelly T, Bates M, Huang Y, Martin C, Skehan S, Canney A, Gallagher M, Smyth P, Brady N, Clarke A, Mohamed B, Norris L, Brooks DA, Brooks RD, Heatlie JK, Selemidis S, Hanniffy S, Dixon E, Sheils O, O'Toole SA, O'Leary JJ., The induction of a mesenchymal phenotype by platelet cloaking of cancer cells is a universal phenomenon., Translational oncology, 14, (12), 2021, p101229Journal Article, 2021, DOI
• Sabol M, Calleja-Agius J, Di Fiore R, Suleiman S, Ozcan S, Ward MP, Ozreti" P., (In)Distinctive Role of Long Non-Coding RNAs in Common and Rare Ovarian Cancers., Cancers, 13, (20), 2021Journal Article, 2021, DOI
• Ward MP, Abu Saadeh, F, O'Toole S, Marchocki Z, Gleeson N, Norris LA, Optimisation of Thrombin Generation as a Predictive Biomarker for Venous Thromboembolism in Gynaecological Malignancies, Research Practice in Thrombosis and Haemostasis, International Society for Thrombosis and Haemostasis, Dublin, July 2018, 2018Poster, 2018, DOI
• Mark P Ward, Mark Bates, Bashir Mohamed, Tanya Kelly, Roisin O'Connor, Robert Brooks, Doug Brooks, Stavros Selemidis, Celine Ovaere, Jane Tully, Patrick Maguire, Catherine O'Gorman, Waseem Kamran, James Beirne, Feras Saadeh, Noreen Gleeson, Lucy Norris, Cara Martin, Sharon O'Toole, John O'Leary, Isolation and characterisation of circulating tumour cells from ovarian cancer patients, LABORATORY INVESTIGATION, March 2022, 102, (SUPPL 1), SPRINGER NATURE, 2022Poster, 2022, DOI
• Martini C, Logan JM, Sorvina A, Gordon C, Beck AR, S-Y Ung B, Caruso MC, Moore C, Hocking A, Johnson IRD, Li KL, Karageorgos L, Hopkins AM, Esterman AJ, Huzzell C, Brooks RD, Lazniewska J, Hickey SM, Bader C, Parkinson-Lawrence E, Weigert R, Sorich MJ, Tewari P, Martin C, O'Toole S, Bates M, Ward M, Mohammed B, Keegan H, Watson W, Prendergast S, Heffernan S, NiMhaolcatha S, O'Connor R, Malone V, Carter M, Ryan K, Brady N, Clarke A, Sokol F, Prabhakaran S, Stahl J, Klebe S, Samaratunga H, Delahunt B, Selemidis S, Moretti KL, Butler LM, O'Leary JJ, Brooks DA., Aberrant protein expression of Appl1, Sortilin and Syndecan-1 during the biological progression of prostate cancer., Pathology, 2022, pS0031-3025(22)00226-4Journal Article, 2022, DOI
• Jabakhanji, S.B., Boland, F., Ward, M., Biesma, R., Prevalence of early childhood obesity in Ireland: Differences over time, between sexes and across child growth criteria, Pediatric obesity, 17, (11), 2022Journal Article, 2022
• Bates M, Mohamed BM, Ward MP, Kelly TE, O'Connor R, Malone V, Brooks R, Brooks D, Selemidis S, Martin C, O'Toole S, O'Leary JJ., Circulating tumour cells: The Good, the Bad and the Ugly., Biochim Biophys Acta Rev Cancer, 1878, (2), 2023, p188863Journal Article, 2023, DOI , TARA - Full Text
• Mohamed BM, Ward MP, Bates M, Spillane CD, Kelly T, Martin C, Gallagher M, Heffernan S, Norris L, Kennedy J, Saadeh FA, Gleeson N, Brooks DA, Brooks RD, Selemidis S, O'Toole S, O'Leary JJ., Ex vivo expansion of circulating tumour cells (CTCs)., Scientific reports, 13, (1), 2023, p3704 - 3704Journal Article, 2023, DOI
• Ward MP, Ibrahim E, O'Toole S, Gleeson N, Abu Saadeh F, O'Donnell D, Norris LA, Thrombomodulin as a marker for VTE following neoadjuvant chemotherapy, Thrombosis Research, International Congress on Issues in Thrombosis in Cancer , Bergamo, Italy, May 2022, 213, ((6) Supplement 2), Elsevier, 2022, ppS13 - S14Conference Paper, 2022, URL
• Ward MP, O'Toole SA, Abu Saadeh F, Marchocki Z, Ibrahim EM, Martin F, Gleeon N, O'leary JJ, Norris LA, Mechanisms of cancer associated thrombosis in gynaecological cancer patients- tumour or treatment effect?, Research Practice in Thrombosis and Haemostasis, International Society for Thrombosis and Haemostasis, London, July 2022, 6, (Supplement 2), Wiley, 2022, ppPB0752 - PB0752Conference Paper, 2022, URL
• Ward MP, Lochrin SE, Ovarere C, O'Gorman C, Kane LE, Mohamed BM, Bates M, Kelly TE, O'Connor R, Kennedy J, Cadoo K, Kamran W, Beirne J, Abu Saadeh F, Martin CM, Norris LA, O'Toole SA, O'leary JJ, Platelets and immune call cloaking of circulating tumour cells in breast and ovarian cancer, Research Practice in Thrombosis and Haemostasis, International Society for Thrombosis and Haemostasis, London, July 2022, 6, ((supplement 2)), Wiley, 2022, ppPB0931 - PB0931Conference Paper, 2022, URL
• Logan JM, Hopkins AM, Martini C, Sorvina A, Tewari P, Prabhakaran S, Huzzell C, Johnson IRD, Hickey SM, Ung BS, Lazniewska J, Brooks RD, Moore CR, Caruso MC, Karageorgos L, Martin CM, O'Toole S, Bogue Edgerton L, Ward MP, Bates M, Selemidis S, Esterman A, Heffernan S, Keegan H, Ní Mhaolcatha S, O'Connor R, Malone V, Carter M, Ryan K, Clarke A, Brady N, Klebe S, Samaratunga H, Delahunt B, Sorich MJ, Moretti K, Butler LM, O'Leary JJ, Brooks DA., Prediction of Prostate Cancer Biochemical and Clinical Recurrence Is Improved by IHC-Assisted Grading Using Appl1, Sortilin and Syndecan-1., Cancers, 15, (12), 2023, p3215Journal Article, 2023, DOI
• Lazniewska J, Li KL, Johnson IRD, Sorvina A, Logan JM, Martini C, Moore C, Ung BS, Karageorgos L, Hickey SM, Prabhakaran S, Heatlie JK, Brooks RD, Huzzell C, Warnock NI, Ward MP, Mohammed B, Tewari P, Martin C, O'Toole S, Edgerton LB, Bates M, Moretti P, Pitson SM, Selemidis S, Butler LM, O'Leary JJ, Brooks DA., Dynamic interplay between sortilin and syndecan-1 contributes to prostate cancer progression., Scientific reports, 13, (1), 2023, p13489Journal Article, 2023, DOI
• Ward, Mark P, Lewis, Faye, O'Gorman, Catherine, Kelly, Tanya E, Mohamed, Bashir M, Henderson, Brian, Hurley, Sinead, O'Connor, Roisin, Brooks, Robert D, Brooks, Doug A, Selemidis, Stavros, Maguire, Patrick, Kamran, Waseem, Beirne, James P, Saadeh, Feras A, Cadoo, Karen, Norris, Lucy A, Martin, Cara, O'Toole, Sharon A, O'Leary, John J, #836 Liquid biopsy isolation of circulating tumour cells from epithelial ovarian cancer patients and their prognostic significance, European Congress on Gynaecological Oncology, Istanbul, Turkey, BMJ Publishing Group Ltd, 2023Conference Paper, 2023, DOI
• Kelly TE, Spillane CL, Ward MP, Hokamp K, Huang Y, Tewari P, Martin CM, Norris LA, Mohamed BM, Bates M, Brooks R, Selemidis S, Brooks DA, Kamran W, Saadeh FA, O'Toole SA, O'Leary JJ., Plasminogen activator inhibitor 1 is associated with high-grade serous ovarian cancer metastasis and is reduced in patients who have received neoadjuvant chemotherapy., Frontiers in cell and developmental biology, 11, 2023, p1150991Journal Article, 2023, DOI
• Ward, Mark P., O'Toole, Sharon A., O'Leary, John J., Potential role of the CD39-CD73 ATP-adenosine pathway in platelet mediated dissemination of circulating tumour cells, British Journal of Cancer, 2024Journal Article, 2024, DOI
• M Saini, Volga, Oner, Ezgi, Ward, Mark P., Hurley, Sinead, Henderson, Brian David, Lewis, Faye, Finn, Stephen P., Fitzmaurice, Gerard J., O'Leary, John J., O'Toole, Sharon, O'Driscoll, Lorraine, Gately, Kathy, A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer, Molecular Oncology, 2024Journal Article, 2024, DOI
• Lewis F, Beirne J, Henderson B, Norris L, Cadoo K, Kelly T, Martin C, Hurley S, Kanjuga M, O'Driscoll L, Gately K, Oner E, Saini V, Brooks D, Selemidis S, Kamran W, Haughey N, Maguire P, O'Gorman C, Saadeh FA, Ward MP, O'Leary JJ, O'Toole SA., Unravelling the biological and clinical challenges of circulating tumour cells in epithelial ovarian carcinoma., Cancer letters, 2024, p217279Journal Article, 2024
• Hindes MT, McElligott AM, Best OG, Ward MP, Selemidis S, Miles MA, Nturubika BD, Gregory PA, Anderson PH, Logan JM, Butler LM, Waugh DJ, O'Leary JJ, Hickey SM, Thurgood LA, Brooks DA., Metabolic reprogramming, malignant transformation and metastasis: Lessons from chronic lymphocytic leukaemia and prostate cancer., Cancer letters, 611, 2025, p217441Journal Article, 2025, DOI , TARA - Full Text
• Ward MP, Ibrahim EM, O'Toole SA, Marchocki Z, O'Leary JJ, Saadeh FA, Norris LA., Chemotherapy alters thrombomodulin and factor VIIIc expression resulting in acquired activated protein C resistance and enhanced thrombin generation in cancer associated thrombosis., Thrombosis research, 246, 2024, p109251Journal Article, 2024, DOI
• Nturubika BD, Logan J, Johnson IRD, Moore C, Li KL, Tang J, Lam G, Parkinson-Lawrence E, Williams DB, Chakiris J, Hindes M, Brooks RD, Miles MA, Selemidis S, Gregory P, Weigert R, Butler L, Ward MP, Waugh DJJ, O'Leary JJ, Brooks DA., Components of the Endosome-Lysosome Vesicular Machinery as Drivers of the Metastatic Cascade in Prostate Cancer., Cancers, 17, (1), 2024, p43Journal Article, 2024, DOI
• LEWIS, F., BEIRNE, J., HENDERSON, B., NORRIS, L., CADOO, K., KELLY, T., MARTIN, C., HURLEY, S., KANJUGA, M., O'DRISCOLL, L., GATELY, K., ONER, E., SAINI, V. M., BROOKS, D., SELEMIDIS, S., KAMRAN, W., HAUGHEY, N., MAGUIRE, P., O'GORMAN, C., SAADEH, F. A., WARD, M. P., O'LEARY, J. J. & O'TOOLE, S. A., Unravelling the biological and clinical challenges of circulating tumour cells in epithelial ovarian carcinoma, Cancer Letters, 2024Journal Article, 2024, DOI
• LEWIS, F., WARD, M. P., SAADEH, F. A., O'GORMAN, C., MAGUIRE, P. J., BEIRNE, J. P., KAMRAN, W., IBRAHIM, E., NORRIS, L., KELLY, T., HURLEY, S., HENDERSON, B., KANJUGA, M., O'DRISCOLL, L., GATELY, K., ONER, E., SAINI, V. M., CADOO, K., MARTIN, C., O'LEARY, J. J. & O'TOOLE, S. A., A pilot study evaluating the feasibility of enriching and detecting circulating tumour cells from peripheral and ovarian veins in rare epithelial ovarian carcinomas, European Journal of Surgical Oncology, 2025Journal Article, 2025, DOI
• Mark P. Ward and Bashir M. Mohamed and Laura Kane and Mark Bates and Janina Berghoff and Cathy L. Spillane and Tanya Kelly and John Kennedy and Feras A. Saadeh and Karsten Hokamp and Noreen Gleeson and Orla Sheils and Cara Martin and Michael Gallagher and Sean Hannify and Eric P. Dixon and Sharon A. O{\textquotesingle, Abstract 764: Influence of platelets and neutrophils on circulating tumour cells, Clinical Research (Excluding Clinical Trials), 2020Journal Article, 2020, DOI
• Mark P. Ward, F. Park Lewis, C. O"Gorman, Thomas J. Kelly, S. Hurley, Brian E. Henderson, Feras Abu Saadeh, Karen A. Cadoo, John O"Leary, Sharon O"Toole, Prognostic Significance of Circulating Tumour Cells and Disseminating Circulating Tumour Cell Clusters in Epithelial Ovarian Cancer, The Journal of Liquid Biopsy, 1, 2023, p100062 - 100062, p100062-100062Journal Article, 2023, DOI
• Jessica K. Heatlie, Joanna "a"niewska, Courtney R. Moore, I. R. Johnson, Bukuru D. Nturubika, Ruth Williams, Mark P. Ward, John O"Leary, Lisa M. Butler, Doug A. Brooks, Extracellular Vesicles and Tunnelling Nanotubes as Mediators of Prostate Cancer Intercellular Communication, Biomolecules, 15, (1), 2024, p23 - 23, p23-23Journal Article, 2024, DOI
• Raftery NB, Elliott JA, Muldoon C, Ryan C, O'Brien M, Fagan O, Ward M, Donlon NE, Donohoe CL, Ravi N, Buckley M, Murphy T, Patchett S, O'Sullivan J, O'Toole D, Reynolds JV., Tackling Prevention and Early Diagnosis of Esophageal Adenocarcinoma through a National Barrett's Registry and Scientific Network., Annals of surgery, 2025Journal Article, 2025, DOI
• Faye Lewis, Mark P. Ward, Feras Abu Saadeh, John O"Leary, Sharon O"Toole, Reply to: In Reference to "A Pilot Study Evaluating the Feasibility of Enriching and Detecting Circulating Tumour Cells from Peripheral and Ovarian Veins in Rare Epithelial Ovarian Carcinomas", European Journal of Surgical Oncology, 2025, p110206 - 110206, p110206-110206Journal Article, 2025, DOI
• Faye Lewis, Mark P. Ward, Feras Abu Saadeh, Catherine O"Gorman, Patrick Maguire, James Beirne, Waseem Kamran, Elzahra Ibrahim, Rebecca Hunter, Sinéad Hurley, Lucy Norris, Brian E. Henderson, Irene Narinda, Marika Kanjuga, Lorraine O"Driscoll, Kathy Gately, Volga M. Saini, Karen A. Cadoo, Cara Martin, John O"Leary, Sharon O"Toole, Abstract B041: Circulating tumor cells are associated with a shorter disease-free interval in patients with advanced high-grade serous carcinoma undergoing neoadjuvant chemotherapy followed by interval cytoreductive surgery, 85, (18_Supplement), 2025, ppB041 - B041, ppB041-B041Published Abstract, 2025, DOI
• Ciara SMc Nevin, Faye Lewis, C Gorman, Feras Abu Saadeh, John O"Leary, Lucy Norris, Mark P. Ward, Patrick Maguire, Scheryll Alken, Sinéad Hurley, Vicky Donachie, Sharon O"Toole, Karen A. Cadoo, 946 Clinical and histopathologic analysis of young onset ovarian cancer: a tertiary referral centre experience over 18 years, ESMO, 2024, ppA380.2 - A381, ppA380.2-A381Published Abstract, 2024, DOI
• Faye Lewis, Mark P. Ward, Catherine O"Gorman, Brian E. Henderson, Sinéad Hurley, James Beirne, Lorraine O"Driscoll, Ciara S. McNevin, Tanya Kelly, Kathy Gately, Ezgi Öner, Volga M Saini, Lucy Norris, Marika Kanjuga, Cara Martin, Patrick Maguire, Karen A. Cadoo, G. M. McManus, John O"Leary, Sharon O"Toole, 1342 Longitudinal detection of circulating tumour cells in serous and non-serous epithelial ovarian carcinomas, 2024, pA425.1 - A425, pA425.1-A425Conference Paper, 2024, DOI
• Bashir M. Mohamed, Mark P. Ward, Mark Bates, Cathy Spillane, Tanya Kelly, Cara Martin, Michael Gallagher, John Kennedy, Fears Abu Saadeh, Noreen Gleeson, Doug A. Brooks, Robert D. Brooks, Stavros Selemidis, Sean Hannify, Eric P. Dixon, Sharon O"Toole, John O"Leary, 599 Circulating tumour cells in breast and ovarian cancer: size-based isolation and ex vivo expansion, Translational research, 2020, pA132.1 - A132, pA132.1-A132Conference Paper, 2020, DOI
• Ward MP, Lewis F, O'Gorman C, Norris LA, Lochrin SE, Kane LE, Kelly TE, Mohamed BM, Ramesh A, O'Connor R, Kilgour E, Henderson B, Kanjuga M, Hurley S, Edgerton L, Tewari P, Gately K, O'Driscoll L, Hokamp K, Cashman S, McManus G, Brooks DA, Selemidis S, Coleman N, Kennedy J, Kamran W, Beirne JP, Maguire P, Abu Saadeh F, Cadoo K, Martin CM, O'Leary JJ, O'Toole SA., Circulating tumour cells are a prognostic indicator in advanced high-grade serous ovarian cancer and are associated with platelets and immune cells following dissemination., British journal of cancer, 2025Journal Article, 2025, DOI
• Albasanz-García, Pablo, Ward, Mark P., Norris, Lucy A., Mechanisms of anticancer treatment-induced arterial and venous thrombosis., Journal of Thrombosis and Haemostasis, 2025Journal Article, 2025, DOI
• Raftery NB, Ward M, Ravi N, Reynolds JV, Elliott JA, Donohoe CL., Modulation of the Tumour Microenvironment by HER2 in Oesophagogastric Adenocarcinoma: Implications for Tumour Progression, Therapeutic Resistance, and Clinicopathological Outcomes., Cancers, 17, (24), 2025, p3987Journal Article, 2025
• Ciara S. McNevin, Rachel Dillion, Simon J. Hollingsworth, Faye Lewis, Sinéad Hurley, Lucy Norris, Mark P. Ward, Vicky Donachie, Patrick Maguire, Scheryll Alken, Niamh Coleman, Waseem Kamran, Feras Abu Saadeh, Catherine O"Gorman, Deborah Donnell, Tom D"Arcy, John O"Leary, Stephen P. Finn, Sharon O"Toole, Karen A. Cadoo, Genetics And Survival Outcomes In Young-Onset Ovarian Cancer: Insights From An 18-Year Tertiary Referral Center Study, 35, (2), 2025, pp100350 - 100350, pp100350-100350Published Abstract, 2025, DOI
• Mark P. Ward, Tanya Kelly, Faye Lewis, Catherine O"Gorman, Brian E. Henderson, Sinéad Hurley, Marika Kanjuga, Emer Atkinson, Cathal Ó"Brien, Patrick Maguire, Waseem Kamran, James Beirne, Niamh Coleman, Karen A. Cadoo, Feras Abu Saadeh, Lucy Norris, Cara Martin, John O"Leary, Sharon O"Toole, EV021/#894" Mutational analysis of circulating tumour DNA (ctDNA) in high grade serous ovarian cancer (HGSC) using cancer personalised profiling by deep sequencing (CAPP-seq), 2024, pA94 - A94, pA94-A94Journal Article, 2024, DOI
• Faye Lewis, Mark P. Ward, Catherine O"Gorman, Brian E. Henderson, Sinéad Hurley, James Beirne, Lorraine O"Driscoll, Kathy Gately, Ezgi Öner, Volga M Saini, Marika Kanjuga, Lucy Norris, Cara Martin, Tanya Kelly, Patrick Maguire, Feras Abu Saadeh, Waseem Kamran, Karen A. Cadoo, Niamh Haughey, G. M. McManus, John O"Leary, Sharon O"Toole, EV290/#1177" Radiological size of the pelvic mass in high-grade serous carcinomas inversely correlates with circulating tumour cell detection from the ovarian vein at surgery, 2024, pA233.3 - A234, pA233.3-A234Journal Article, 2024, DOI
• Abdul L. Shakerdi, Eileen M. Finnegan, Yonghua Sheng, Karina Vidovic, Jessica M. Logan, Mark P. Ward, Sharon O"Toole, Cara Martin, Stavros Selemidis, Doug A. Brooks, John O"Leary, Prerna Tewari, Crosstalk Between Inflammasome Signalling and Epithelial-Mesenchymal Transition in Cancer and Benign Disease: Mechanistic Insights, Context-Dependence, and Therapeutic Opportunities, Cells, 14, (20), 2025, p1594 - 1594, p1594-1594Review Article, 2025, DOI
• Caroline Marion, Irene Narinda, Marika Kanjuga, Lauren Mcmahon, Faye Lewis, Sinéad Hurley, Yvonne O'Meara, Bridget Carr, Feras Abu Saadeh, Patrick J. Maguire, Lucy A. Norris, C. E. Martin, Karen A. Cadoo, Catherine O'Gorman, Joanne Lysaght, John J. O'Leary, Melissa J. Conroy, Mark P. Ward, O'Toole Sharon, Elucidating the utility of natural killer cell soluble ligands in high grade serous ovarian cancer to predict platinum resistance, International Journal of Gynecological Cancer, 36, (2), 2026, p104254 - 104254, p104254-104254Journal Article, 2026, DOI
• Brian Henderson, Lauren Mc Mahon, Faye Lewis, Caroline Marion, Sinéad Hurley, Irene Narinda, Lucy A. Norris, Marika Kanjuga, Neil T. Conlon, Feras Abu Saadeh, Catherine O'Gorman, Patrick Maguire, Waseem Kamran, Karen A. Cadoo, Niamh Coleman, John O"Leary, Mark P. Ward, O'Toole Sharon, A workflow to assess ADC target expression on circulating tumour cells in epithelial ovarian cancer, International Journal of Gynecological Cancer, 36, (2), 2026, p104230 - 104230, p104230-104230Journal Article, 2026, DOI
• Marika Kanjuga, Faye Lewis, Caroline Marion, Mark P. Ward, Irene Narinda, Lauren Mcmahon, Sinéad Hurley, Cara M. Martin, John J. O'Leary, O'Toole Sharon, Brian David Henderson, Optimising an aptamer-based serum biomarker discovery platform for ovarian cancer; using HRP as a model target, International Journal of Gynecological Cancer, 36, (2), 2026, p104244 - 104244, p104244-104244Journal Article, 2026, DOI
• Henderson B.D., McMahon L., Lewis F., Marion C., Hurley S., Gately K., Narinda I., Kanjuga M., Norris L., Martin C., Conlon N., O'Driscoll L., Saadeh F.A., O'Gorman C., Maguire P.J., Kamran W., Ibrahim E., Cadoo K.A., Coleman N., O'Leary J.J., Ward M.P., O'Toole S.A., A workflow for assessing antibody-drug conjugate target expression on circulating tumour cells from triple-negative breast cancer and epithelial ovarian cancer patients, Journal of Liquid Biopsy, 13, 2026Journal Article, 2026, DOI

• Mark P. Ward, Bashir M. Mohamed, Laura Kane, Mark Bates, Janina Berghoff, Cathy L. Spillane, Tanya Kelly, John Kennedy, Feras A. Saadeh, Karsten Hokamp, Noreen Gleeson, Orla Sheils, Cara Martin, Michael Gallagher, Sean Hannify, Eric P. Dixon, Sharon A. O'Toole and John J. O'Leary, Influence of platelets and neutrophils on circulating tumour cells, AACR Annual Meeting , Philadelphia, PA, 2020; April 27-28, 80, (16), American Association for Cancer Research, 2020Poster, URL
• MP Ward, JP Spiers, Modulation of MMP-9 and TIMP-1 expression by Protein Phosphatase in Hep3B and LX-2 cell lines., British Pharmacological Society, Modulation of MMP-9 and TIMP-1 expression by Protein Phosphatase in Hep3B and LX-2 cell lines., London, December 2013, 2013Conference Paper
• MP Ward, JP Spiers, Increased Cancerous Inhibitor of PP2A (CIP2A) Expression in Hepatocellular Carcinoma Cells Following Co-Culture With Anti-Inflammatory Macrophages., Increased Cancerous Inhibitor of PP2A (CIP2A) Expression in Hepatocellular Carcinoma Cells Following Co-Culture With Anti-Inflammatory Macrophages., London, 2015Conference Paper

• Title

  Mechanism of Immunotherapy-Associated Thrombosis in Cancer
  Summary

  Immune checkpoint inhibitors (ICIs) have transformed the treatment of many cancers by enabling the immune system to recognise and attack tumour cells more effectively. However, their increasing use has revealed important complications, including an increased risk of blood clots in both veins and arteries. These events can have serious consequences for patients, yet the biological mechanisms linking immunotherapy to thrombosis remain poorly understood.
  
  Our research investigates how changes in immune function during cancer immunotherapy may influence the processes that regulate blood clotting and vascular health. In particular, we are interested in how activated immune cells and the inflammatory signals they produce interact with the vascular endothelium, the cell layer lining blood vessels that plays a central role in maintaining the balance between normal anticoagulant and procoagulant activity.
  
  The project explores the hypothesis that excessive immune activation during ICI treatment can disturb this balance, promoting an inflammatory and prothrombotic vascular environment. A particular focus is the interaction between activated T cells, inflammatory signalling pathways and natural anticoagulant mechanisms that normally protect the circulation from inappropriate clot formation.
  
  By combining computational approaches, laboratory models and investigation of samples from patients receiving cancer immunotherapy, this research aims to build a clearer understanding of the immune and vascular mechanisms underlying immunotherapy-associated thrombosis.
  
  Ultimately, understanding why thrombosis develops in some patients receiving ICIs could help identify new biomarkers of treatment-related vascular complications and reveal opportunities for pharmacological intervention. The longer-term goal is to support safer cancer immunotherapy by reducing thrombotic complications while preserving the powerful anticancer immune responses that make these treatments effective.
  Funding Agency

  Trinity Research Doctorate Award
• Title

  Liquid Biopsy for Immunotherapy and Antibody-Drug Conjugate Response in Triple-Negative Breast Cancer
  Summary

  Immunotherapy, including immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs), is providing new treatment options for patients with triple-negative breast cancer (TNBC). However, responses vary considerably between patients, and there remains a need for better biomarkers to identify those most likely to benefit and to monitor response during treatment.
  
  Our research explores the potential of liquid biopsy as a minimally invasive approach to understanding treatment response in TNBC. In particular, we are interested in circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA), which can provide information about a patient"s cancer through a blood sample and may capture changes in tumour biology over the course of treatment.
  
  By studying these circulating biomarkers, we aim to better understand how TNBC responds to immunotherapy and other emerging treatments, and whether changes detected in the blood can provide an earlier indication of treatment response or resistance. We are also interested in using patient-derived and laboratory models to investigate how individual tumours respond to newer cancer therapies.
  
  Ultimately, this work aims to support the development of more personalised approaches to TNBC treatment, using liquid biopsy to help understand tumour behaviour, monitor treatment response and inform the future development of new therapeutic strategies.
  Funding Agency

  Trinity St James's Cancer Institute
• Title

  PINPOINT: PredIction aNd Prevention Of Venous Thrombosis durINg chemotherapy combining dynamic biomarker risk assessment, patient perspectives and health technology assessment.
  Summary

  Venous thromboembolism (VTE) is the leading cause of non-cancer death in patients with cancer. Patients are particularly at risk during chemotherapy, with rates of up to 20% reported. Guidelines recommend primary prophylaxis with direct oral anticoagulants (DOACs) in intermediate- and high-risk patients undergoing chemotherapy, following risk assessment using a validated risk score such as the Khorana score. However, the Khorana score performs poorly in lung, ovarian and gastric cancers and relies on a single assessment at the start of therapy.
  
  The development of VTE is a dynamic process that cannot be accurately represented by a single risk assessment. Our data suggest that markers of procoagulant activity are implicated in chemotherapy-associated VTE and could be measured serially as predictive biomarkers. This may provide a more effective method of identifying patients at risk of VTE and facilitate targeted prophylaxis.
  
  Prophylaxis with DOACs carries a risk of bleeding, and decisions regarding prophylaxis should therefore be shared between the doctor and patient. However, studies have shown that patients with cancer receive limited information about VTE risk, and tools to support decision making in this area are lacking. Cost is also an important consideration for both the health service and the patient.
  
  In this study, we will measure procoagulant biomarker levels serially during chemotherapy as dynamic predictors of VTE, investigate the prothrombotic mechanisms involved in chemotherapy-associated VTE, identify patient needs and priorities for shared decision making regarding prophylaxis during chemotherapy, and perform a cost-benefit analysis of biomarker screening and targeted VTE prophylaxis.
  
  This study aims to develop dynamic predictive biomarkers for VTE during chemotherapy and to understand patient priorities regarding VTE prevention. Identification of high-risk patients, together with an improved understanding of patient priorities and costs, will support effective shared decision making between doctors and patients, ultimately reducing the burden of VTE in cancer.
  Funding Agency

  Health Research Board
• Title

  Development of a Personalised Near Patient (PNP) Allogeneic NK-Cell Immunotherapy (PNPNKimunnoT) for Platinum Resistant High Grade Serous Ovarian Cancer.
  Summary

  High-grade serous ovarian cancer (HGSC), which includes cancers arising from the ovary, fallopian tube and peritoneum, is the most common and aggressive form of epithelial ovarian cancer. Despite advances in surgery, chemotherapy and maintenance treatments, most patients experience disease recurrence, and the development of platinum-resistant disease remains a major clinical challenge. New therapeutic approaches are therefore urgently needed.
  
  Natural killer (NK) cells are an important component of the immune system's defence against cancer. Unlike some other immune cells, NK cells can recognise and destroy cancer cells without requiring recognition of a specific tumour antigen. This makes them particularly attractive for the development of cellular immunotherapies, including potential off-the-shelf treatments.
  
  A major challenge in ovarian cancer is that tumours can create an environment that limits the ability of immune cells to enter and function effectively within the tumour. HGSC is frequently characterised as an immune-excluded tumour, and patients with lower levels of tumour-infiltrating NK cells tend to have poorer outcomes. Understanding the biological signals that regulate NK cell recruitment and activity within ovarian tumours could therefore provide new opportunities to improve immunotherapy.
  
  Our research investigates the relationship between HGSC and NK cell biology, with a particular interest in understanding how the tumour microenvironment influences NK cell recruitment, activation and anti-cancer function. We aim to use insights gained directly from ovarian cancer to inform the development of improved NK cell-based therapeutic approaches.
  
  By bringing together patient-focused cancer biology and cellular immunotherapy, this research seeks to overcome some of the barriers that currently limit immune-based treatments for ovarian cancer. Ultimately, the goal is to contribute to the development of more effective treatment options for patients with platinum-resistant HGSC.
  Funding Agency

  HRCI-HRB Joint Funding Scheme

Biochemistry and cell biology, Cancer,

• IACR Senior Investigator Award 2024

• European Association for Cancer Research Present
• The Irish Society for Gynaecological Oncology (ISGO) Present
• British Pharmacological Society (Full Member) Present